Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
CCXI's Cash to Debt is ranked higher than
82% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 36.54 vs. CCXI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CCXI' s Cash to Debt Range Over the Past 10 Years
Min: 6.43  Med: 403.98 Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: 12.09
M-Score: -4.02
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -48.02
CCXI's ROE (%) is ranked lower than
62% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: -30.40 vs. CCXI: -48.02 )
Ranked among companies with meaningful ROE (%) only.
CCXI' s ROE (%) Range Over the Past 10 Years
Min: -42.81  Med: -30.25 Max: -4.02
Current: -48.02
-42.81
-4.02
ROA (%) -44.82
CCXI's ROA (%) is ranked lower than
65% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -26.44 vs. CCXI: -44.82 )
Ranked among companies with meaningful ROA (%) only.
CCXI' s ROA (%) Range Over the Past 10 Years
Min: -35.64  Med: -28.15 Max: -3.07
Current: -44.82
-35.64
-3.07
ROC (Joel Greenblatt) (%) -4233.04
CCXI's ROC (Joel Greenblatt) (%) is ranked lower than
78% of the 869 Companies
in the Global Biotechnology industry.

( Industry Median: -389.41 vs. CCXI: -4233.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CCXI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3598.39  Med: -2639.91 Max: -22.36
Current: -4233.04
-3598.39
-22.36
» CCXI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

CCXI Guru Trades in Q1 2015

Jim Simons 81,700 sh (+27.81%)
Chuck Royce 70,000 sh (unchged)
» More
Q2 2015

CCXI Guru Trades in Q2 2015

Steven Cohen 400 sh (New)
Jim Simons 127,377 sh (+55.91%)
Chuck Royce 70,000 sh (unchged)
» More
Q3 2015

CCXI Guru Trades in Q3 2015

Steven Cohen Sold Out
Chuck Royce 55,000 sh (-21.43%)
Jim Simons 24,700 sh (-80.61%)
» More
Q4 2015

CCXI Guru Trades in Q4 2015

Jim Simons 44,300 sh (+79.35%)
Chuck Royce 33,300 sh (-39.45%)
» More
» Details

Insider Trades

Latest Guru Trades with CCXI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.98
CCXI's P/B is ranked higher than
67% of the 795 Companies
in the Global Biotechnology industry.

( Industry Median: 2.92 vs. CCXI: 1.98 )
Ranked among companies with meaningful P/B only.
CCXI' s P/B Range Over the Past 10 Years
Min: 1.32  Med: 2.74 Max: 4.98
Current: 1.98
1.32
4.98
Current Ratio 13.40
CCXI's Current Ratio is ranked higher than
82% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. CCXI: 13.40 )
Ranked among companies with meaningful Current Ratio only.
CCXI' s Current Ratio Range Over the Past 10 Years
Min: 6.61  Med: 10.88 Max: 19.54
Current: 13.4
6.61
19.54
Quick Ratio 13.40
CCXI's Quick Ratio is ranked higher than
83% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.52 vs. CCXI: 13.40 )
Ranked among companies with meaningful Quick Ratio only.
CCXI' s Quick Ratio Range Over the Past 10 Years
Min: 6.61  Med: 10.88 Max: 19.54
Current: 13.4
6.61
19.54

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.38
CCXI's Price/Net Cash is ranked higher than
75% of the 475 Companies
in the Global Biotechnology industry.

( Industry Median: 4.87 vs. CCXI: 2.38 )
Ranked among companies with meaningful Price/Net Cash only.
CCXI' s Price/Net Cash Range Over the Past 10 Years
Min: 1.97  Med: 3.93 Max: 7.68
Current: 2.38
1.97
7.68
Price/Net Current Asset Value 2.37
CCXI's Price/Net Current Asset Value is ranked higher than
75% of the 595 Companies
in the Global Biotechnology industry.

( Industry Median: 4.65 vs. CCXI: 2.37 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CCXI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.95  Med: 3.90 Max: 7.47
Current: 2.37
1.95
7.47
Price/Tangible Book 1.98
CCXI's Price/Tangible Book is ranked higher than
73% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. CCXI: 1.98 )
Ranked among companies with meaningful Price/Tangible Book only.
CCXI' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.56  Med: 3.27 Max: 4.92
Current: 1.98
1.56
4.92
Earnings Yield (Greenblatt) (%) -51.30
CCXI's Earnings Yield (Greenblatt) (%) is ranked lower than
87% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -7.80 vs. CCXI: -51.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CCXI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -68.25  Med: 0.00 Max: 0
Current: -51.3
-68.25
0

More Statistics

Revenue(Mil) $6
EPS $ -1.10
Beta1.86
Short Percentage of Float12.80%
52-Week Range $3.23 - 9.46
Shares Outstanding(Mil)44.13

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:2CX.Germany,
Chemocentryx Inc was incorporated in the state of Delaware on November 8, 1996. The Company is a biopharmaceutical company engaged in discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. It currently has five drug candidates in clinical development. CCX168 —Targeting the chemoattractant receptor known as C5aR, CCX168 has successfully completed and reported positive clinical data from the first two steps of a three-step Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody, or ANCA, associated renal vasculitis, or AARV. CCX140 — Targeting the chemokine receptor known as CCR2, CCX140 is currently in Phase II clinical development in patients with diabetic nephropathy, a form of kidney disease. Vercirnon (also known as Traficet-EN, or CCX282) —Targeting the chemokine receptor known as CCR9, vercirnon is its drug candidate for the treatment of patients with moderate-to-severe Crohn's disease. CCX872 — its second generation orally administered inhibitor targeting CCR2, CCX872 is expected to complete Phase I clinical development. CCX507 — its second generation CCR9 inhibitor for the treatment of inflammatory bowel disease, or IBD, CCX507 is expected to complete Phase I clinical development. Its current drug candidates are manufactured using common chemical engineering and synthetic processes from readily available raw materials. It rely on contract manufacturing organizations to produce its drug candidates in accordance with the FDA's current good manufacturing practices, or cGMP, regulations for use in its clinical trials. The Company competes in the pharmaceutical, biotechnology and other related markets that address AARV, chronic kidney disease and diabetic nephropathy, IBD, rheumatoid arthritis, other autoimmune diseases and inflammatory disorders, and cancer. The Company competes with the pharmaceutical companies that currently sell or are developing drugs include AbbVie, Amgen, AstraZeneca, Biogen Idec, Bayer, Bristol-Myers Squibb, Elan, Roche/Genentech, GSK, Johnson & Johnson, Merck, Merck Serono, Takeda, Novartis, Pfizer, Sanofi and Teva. The Company and its manufacturers are subject to federal, state and local and foreign laws and regulations governing the use, generation, manufacture, storage, handling and disposal of these hazardous materials.
» More Articles for CCXI

Headlines

Articles On GuruFocus.com
Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 

More From Other Websites
ChemoCentryx (CCXI) Rises: Stock Adds 8.2% in Session Feb 10 2016
ChemoCentryx to Present at the 34th Annual J.P. Morgan Healthcare Conference Jan 07 2016
ChemoCentryx rare-disease drug as effective as standard of care Jan 06 2016
ChemoCentryx drug meets main goal in mid-stage study Jan 06 2016
ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally... Jan 06 2016
Biotechnology Equities Update -- Arena Pharma, Compugen, ChemoCentryx, and Concert Pharma Dec 23 2015
A Change in Tides - Analyst Notes on Hemisphere Media Group, AngioDynamics, ChemoCentryx and... Dec 17 2015
CHEMOCENTRYX, INC. Financials Dec 08 2015
What Do Hedge Funds Think of Blount International, Inc. (BLT)? Dec 02 2015
ChemoCentryx (CCXI) Shares March Higher, Can It Continue? Dec 02 2015
Hedge Funds Are Crazy About Panhandle Oil and Gas Inc. (PHX) Nov 30 2015
Hedge Funds Are Selling Navios Maritime Holdings Inc. (NM) Nov 26 2015
What Makes a Chart Move? – Research on Zix, DavidsTea, ChemoCentryx and Genie Energy Nov 18 2015
ChemoCentryx reports 3Q loss Nov 09 2015
ChemoCentryx reports 3Q loss Nov 09 2015
ChemoCentryx Inc Earnings Call scheduled for 5:00 pm ET today Nov 09 2015
ChemoCentryx to Hold Third Quarter 2015 Financial Results Conference Call on Monday, November 9,... Nov 09 2015
CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 09 2015
ChemoCentryx to Present at the Rodman & Renshaw 17th Annual Global Investment Conference Sep 02 2015
Edited Transcript of CCXI earnings conference call or presentation 6-Aug-15 9:00pm GMT Aug 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK